Management and Successful Desensitization in a Patient with Abatacept-Induced Anaphylaxis

Özet

Abatacept is a fusion protein that blocks T cell activation. It is used in a variety of conditions including organ transplantation, immunedeficiency, and autoimmune diseases. Even though abatacept-induced adverse events are observed, hypersensitivity reactions arerare. Desensitization protocols that can be implemented in the case of hypersensitivity reactions are present in the literature for manybiological agents. However, a desensitization protocol for abatacept has not yet been established.Our patient, who was started on one of the biological agents, abatacept, for rheumatoid arthritis due to insufficient response to diseasemodifying antirheumatic drugs, developed immediate hypersensitivity reaction with the first dose. Since it was planned to continuethe treatment, abatacept desensitization was performed. The rapid desensitization protocol performed with prior premedication wassuccessful and the patient was able to receive subsequent doses of abatacept using the same protocol.